- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback